We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+14.29%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$2.45B
AUM Growth
+$519M
Cap. Flow
-$118M
Cap. Flow %
-4.81%
Top 10 Hldgs %
32.76%
Holding
158
New
53
Increased
22
Reduced
25
Closed
33

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$90.2M
2
LH icon
Labcorp
LH
+$65.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$53.4M
4
ABBV icon
AbbVie
ABBV
+$51.8M
5
ITMN
INTERMUNE INC
ITMN
+$35.3M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$43.2M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$41.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.6M
4
GMED icon
Globus Medical
GMED
+$34.2M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 50.5%
2 Miscellaneous 47.73%
3 Technology 1.21%
4 Financials 0.56%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
76
uniQure
QURE
$3.09B
$5.45M 0.22%
+350,000
New +$5.58M
XOMA
77
CALL
DELISTED
Xoma
XOMA
$5.21M 0.21%
+50,000
New +$7.26M
VYNT
78
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$4.8M 0.2%
2,120
-241
-10% -$617K
LPDX
79
DELISTED
LIPOSCIENCE INC COM
LPDX
$4.41M 0.18%
1,382,350
– –
NSPH
80
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$4.3M 0.18%
100,000
-137,346
-58% -$6.49M
MNKD icon
81
PUT
MannKind Corp
MNKD
$1.31B
$4.02M 0.16%
+200,000
New +$5.69M
RIGL icon
82
Rigel Pharmaceuticals
RIGL
$909M
$3.99M 0.16%
102,744
+26,376
+35% +$940K
DSCI
83
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$3.8M 0.16%
+300,000
New +$3.88M
RVNC
84
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.68M 0.15%
+116,689
New +$3.65M
EGRX
85
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.63M 0.15%
+284,653
New +$3.86M
BIIB icon
86
Biogen
BIIB
$32.6B
$3.59M 0.15%
+11,750
New +$3.73M
ITCI
87
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.12M 0.13%
+171,437
New +$3.09M
TENX icon
88
Tenax Therapeutics
TENX
$72.6M
$3.05M 0.12%
+17
New +$3.37M
VIRX
89
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.01M 0.12%
+2,170
New +$2.52M
GYRE icon
90
Gyre Therapeutics
GYRE
$727M
$2.93M 0.12%
783
– –
OCRX
91
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.75M 0.11%
261,119
+50,000
+24% +$715K
ILMN icon
92
Illumina
ILMN
$33B
$2.63M 0.11%
+18,193
New +$2.67M
TNXP icon
93
Tonix Pharmaceuticals
TNXP
$225M
– –
0
– –
PTN
94
Palatin Technologies
PTN
$22.6M
$2.46M 0.1%
1,600
– –
TXMD icon
95
TherapeuticsMD
TXMD
$25.6M
$2.37M 0.1%
+7,521
New +$2.39M
MRGE
96
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$2.34M 0.1%
+959,580
New +$2.28M
EXEL icon
97
CALL
Exelixis
EXEL
$14.6B
$1.77M 0.07%
+500,000
New +$3.4M
REGN icon
98
Regeneron Pharmaceuticals
REGN
$85.2B
$1.44M 0.06%
+4,799
New +$1.48M
EXEL icon
99
Exelixis
EXEL
$14.6B
$1.42M 0.06%
+400,000
New +$2.72M
A icon
100
Agilent Technologies
A
$42.5B
$1.4M 0.06%
+34,950
New +$1.44M
2 3
4
5 6

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q1 2014 Portfolio in Review

As of Q1 2014, Deerfield Management held 158 positions worth $2.45B, up 27% from $1.93B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $118M in Q1 2014, closing 33 positions and reducing 25 holdings. Its most notable exit was Humana, an estimated $43.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 48% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Deerfield Management opened a new position in Dicerna Pharmaceuticals, Inc. worth $68.6M.

  • Deerfield Management's largest Q1 2014 buy was Dicerna Pharmaceuticals, Inc.: 2,428,569 shares worth $68.6M.
  • Deerfield Management added most to Insmed in Q1 2014, an estimated $18.3M increase.
  • Deerfield Management's biggest Q1 2014 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $41.1M.
  • Deerfield Management fully exited Humana in Q1 2014, selling an estimated $43.2M.
  • Deerfield Management's ten largest holdings make up 33% of its $2.45B portfolio in Q1 2014.
  • Deerfield Management opened 53 new positions and closed 33 in Q1 2014.
  • Deerfield Management's portfolio value rose 27% quarter-over-quarter to $2.45B.

Based on Deerfield Management's 13F filing for Q1 2014, filed 15 May 2014.